3. Regorafenib (Stivarga) - Summary of product characteristics. Bayer Pharma AG, Germany.
23. Poole CD et al. Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomised, double-bline, placebo-controlled phase III study of regorafenib versus placebo. Gastric Cancer. 2015;18:627-634.
25. Saponara M et al. Treatment for gastrointestinal stromal tumors that are resistant to standard therapies. Future Oncol. (2014) 10(13), 2045–2059

Regorafenib (Stivarga)